Pharmaceutical

Microparticle analysis: methods and uses in the pharmac...

Particle analysis on a micro-scale is a significant topic in several fields of a...

Why health care needs to shift its thinking on AI, FDA’...

In the latest edition of STAT's Health Tech newsletter: Why health care needs to...

Who’s in charge of the White House Covid response after...

The White House is in the middle of setting up a new pandemic response office, b...

STAT+: What FDA mandate? Sun Pharma halts shipments fro...

The FDA has found that a Sun Pharmaceuticals facility in India failed to comply ...

STAT+: Gilead defeats federal government in closely wat...

A U.S. court jury handed a major win to Gilead Sciences on Tuesday in a closely ...

Breast cancer screening should begin at 40, not 50, fed...

The new guidelines, which recommend all women begin screening mammography at age...

STAT+: Pharmalittle: Big pharma maps legal strategy aga...

The number of layoffs in the U.S. pharmaceutical industry continued at a brisk r...

STAT+: What to know about a pivotal FDA hearing on Sare...

Here's what to know about the upcoming FDA committee hearing on Sarepta's gene t...

STAT+: Q&A: Sen. Sanders on insulin costs and his commi...

"Both [drugmakers and PBMs] share major responsibility for the outrageously high...

STAT+: ‘Hard to catch up’: FDA commissioner on regulati...

“I think we’re behind, and it’s going to be really hard to catch up,” FDA Commis...

Opinion: The IRA’s nonsensical distinction between smal...

Clearly, legislative policy has not kept pace with the rapid evolution in drug d...

An artist uses the canvas to make sense of her partner’...

"Sam is also caring for me a lot of the time, especially if I let him. He tells ...

Opinion: Health care coaches are the next big thing. Th...

Basically anyone can call themselves a “health coach” and start taking on clients.

STAT+: EQRx abandons business plan around drug pricing,...

EQRx, a company that aimed to lower drug prices by introducing inexpensive me-to...

Gail Wilensky on the Geisinger deal, the earnings bonan...

This week's Health Care Inc. tackles the "why" behind the Kaiser Permanente-Geis...

‘Robbing Peter to pay Paul’: Obesity experts debate ris...

Amid rising demand for drugs like Wegovy and Ozempic that can lead to significan...